Clinical and experimental links between diabetes and glaucoma

Clinical and Experimental Optometry

Volumn 94, Issue 1, 2011, Pages 4-23

  Wong, Vickie H Y ^a   Bui, Bang V ^a   Vingrys, Algis J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Diabetes; Dyslipidaemia; Ganglion cells; Glaucoma; Hyperglycaemia; Intraocular pressure; Retina

Indexed keywords

POLYMER; POLYOL; SORBITOL;

ANIMAL; APOPTOSIS; CELL DEATH; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE MODEL; DISEASE PREDISPOSITION; DYSLIPIDEMIA; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; METABOLISM; NERVE TRACT; OPTIC NERVE DISEASE; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; RETINA; RETINA GANGLION CELL; REVIEW; RISK FACTOR; VISION;

ANIMALS; APOPTOSIS; CELL DEATH; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; DYSLIPIDEMIAS; GLAUCOMA; HUMANS; NEURAL PATHWAYS; OCULAR HYPERTENSION; OPTIC NERVE DISEASES; OXIDATIVE STRESS; POLYMERS; RETINA; RETINAL GANGLION CELLS; RISK FACTORS; SORBITOL; VISION, OCULAR;

EID: 78650697903     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2010.00546.x     Document Type: Review

References (277)

1. Fletcher EL, Phipps JA, Wilkinson-Berka JL. Dysfunction of retinal neurons and glia during diabetes. Clin Exp Optom 2005; 88: 132-145.
2. Mitchell P, Suriya F, Wong TY, Chua B, Patel I, Ojaimi E. Clinical Practice Guidelines for the Management of Diabetic Retinopathy. National Health and Medical Research Council 2010. [cited 19 November 2009] Available from.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
4. Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 2006; 90: 272-275.
5. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 283-290.
6. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Caldwell RW. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-455.
7. Watkins PJ. Retinopathy. BMJ 2003; 326: 924-926.
8. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532.
9. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520-526.
10. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55: 1463-1469.
11. Ruppert K, Roberts MS, Orchard TJ, Zgibor JC. Cardiovascular disease risk prediction in type 1 diabetes: accounting for the differences. Diabetes Res Clin Pract 2007; 78: 234-237.
12. Cheung N, Wang JJ, Klein R, Couper DJ, Sharrett AR, Wong TY. Diabetic retinopathy and the risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Diabetes Care 2007; 30: 1742-1746.
13. Wong TY, Klein R, Couper DJ, Cooper LS, Shahar E, Hubbard LD, Wofford MR et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 2001; 358: 1134-1140.
14. Ding C, He Q, Li PA. Activation of cell death pathway after a brief period of global ischemia in diabetic and non-diabetic animals. Exp Neurol 2004; 188: 421-429.
15. Li ZG, Britton M, Sima AA, Dunbar JC. Diabetes enhances apoptosis induced by cerebral ischemia. Life Sci 2004; 76: 249-262.
16. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-393.
17. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267.
18. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999; 18: 39-57.
19. de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Witteman JC, Hofman A, de Jong PT. Is diabetes mellitus a risk factor for open-angle glaucoma? The Rotterdam Study. Ophthalmology 2006; 113: 1827-1831.
20. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363: 1711-1720.
21. Coleman AL. Glaucoma. Lancet 1999; 354: 1803-1810.
22. Macknight AD, McLaughlin CW, Peart D, Purves RD, Carre DA, Civan MM. Formation of the aqueous humor. Clin Exp Pharmacol Physiol 2000; 27: 100-106.
23. Civan MM, Macknight AD. The ins and outs of aqueous humour secretion. Exp Eye Res 2004; 78: 625-631.
24. Sommer A. Intraocular pressure and glaucoma. Am J Ophthalmol 1989; 107: 186-188.
25. Burgoyne CF, Downs JC, Bellezza AJ, Suh JK, Hart RT. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog Retin Eye Res 2005; 24: 39-73.
26. Quigley HA, Flower RW, Addicks EM, McLeod DS. The mechanism of optic nerve damage in experimental acute intraocular pressure elevation. Invest Ophthalmol Vis Sci 1980; 19: 505-517.
27. Quigley HA, Addicks EM. Chronic experimental glaucoma in primates. II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Invest Ophthalmol Vis Sci 1980; 19: 137-152.
28. Quigley H, Anderson DR. The dynamics and location of axonal transport blockade by acute intraocular pressure elevation in primate optic nerve. Invest Ophthalmol 1976; 15: 606-616.
29. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 764-774.
30. Quigley HA, McKinnon SJ, Zack DJ, Pease ME, Kerrigan-Baumrind LA, Kerrigan DF, Mitchell RS. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 2000; 41: 3460-3466.
31. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol 1994; 39: 23-42.
32. Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J Neurobiol 2004; 58: 341-354.
33. Burgoyne CF, Downs JC. Premise and prediction: how optic nerve head biomechanics underlies the susceptibility and clinical behavior of the aged optic nerve head. J Glaucoma 2008; 17: 318-328.
34. Geijer C, Bill A. Effects of raised intraocular pressure on retinal, prelaminar, laminar and retrolaminar optic nerve blood flow in monkeys. Invest Ophthalmol Vis Sci 1979; 18: 1030-1042.
35. Kiel JW, van Heuven WA. Ocular perfusion pressure and choroidal blood flow in the rabbit. Invest Ophthalmol Vis Sci 1995; 36: 579-585.
36. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, Renard JP et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002; 21: 359-393.
37. Emre M, Orgul S, Gugleta K, Flammer J. Ocular blood flow alteration in glaucoma is related to systemic vascular dysregulation. Br J Ophthalmol 2004; 88: 662-666.
38. Kawai SI, Vora S, Das S, Gachie E, Becker B, Neufeld AH. Modeling of risk factors for the degeneration of retinal ganglion cells after ischemia/reperfusion in rats: effects of age, caloric restriction, diabetes, pigmentation and glaucoma. FASEB J 2001; 15: 1285-1287.
39. Osborne NN, Melena J, Chidlow G, Wood JP. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br J Ophthalmol 2001; 85: 1252-1259.
40. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. Ophthalmology 1994; 101: 1851-1855.
41. Cockburn DM. Diagnosis and management of open angle glaucoma: suggested guidelines for optometrists. Clin Exp Optom 2000; 83: 119-127.
42. Kern TS, Barber AJ. Retinal ganglion cells in diabetes. J Physiol 2008; 586: 4401-4408.
43. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035-2038.
44. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8-13.
45. Liew G, Wang JJ. Retinal vascular signs in diabetes and hypertension-review. Arq Bras Endocrinol Metabol 2007; 51: 352-362.
46. Armstrong JR, Daily RK, Dobson HL, Girard LJ. The incidence of glaucoma in diabetes mellitus. A comparison with the incidence of glaucoma in the general population. Am J Ophthalmol 1960; 50: 55-63.
47. Becker B. Diabetes mellitus and primary open-angle glaucoma. The XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol 1971; 1: 1-16.
48. Tielsch JM, Katz J, Quigley HA, Javitt JC, Sommer A. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Survey. Ophthalmology 1995; 102: 48-53.
49. Klein BE, Klein R, Moss SE. Intraocular pressure in diabetic persons. Ophthalmology 1984; 91: 1356-1360.
50. Klein BE, Klein R, Jensen SC. Open-angle glaucoma and older-onset diabetes. The Beaver Dam Eye Study. Ophthalmology 1994; 101: 1173-1177.
51. Kawase K, Tomidokoro A, Araie M, Iwase A, Yamamoto T. Ocular and systemic factors related to intraocular pressure in Japanese adults: the Tajimi study. Br J Ophthalmol 2008; 92: 1175-1179.
52. Ellis JD, Evans JM, Ruta DA, Baines PS, Leese G, MacDonald TM, Morris AD. Glaucoma incidence in an unselected cohort of diabetic patients: is diabetes mellitus a risk factor for glaucoma? DARTS/MEMO collaboration. Diabetes Audit and Research in Tayside Study. Medicines Monitoring Unit. Br J Ophthalmol 2000; 84: 1218-1224.
53. Oshitari T, Fujimoto N, Hanawa K, Adachi-Usami E, Roy S. Effect of chronic hyperglycemia on intraocular pressure in patients with diabetes. Am J Ophthalmol 2007; 143: 363-365.
54. Bankes JL. Ocular tension and diabetes mellitus. Br J Ophthalmol 1967; 51: 557-561.
55. Dielemans I, de Jong PT, Stolk R, Vingerling JR, Grobbee DE, Hofman A. Primary open-angle glaucoma, intraocular pressure, and diabetes mellitus in the general elderly population. The Rotterdam Study. Ophthalmology 1996; 103: 1271-1275.
56. Mitchell P, Smith W, Chey T, Healey PR. Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology 1997; 104: 712-718.
57. Ozcura F, Aydin S. Is diabetes mellitus a risk factor or a protector for primary open angle glaucoma? Med Hypotheses 2007; 69: 233-234.
58. Kahn HA, Leibowitz HM, Ganley JP, Kini MM, Colton T, Nickerson RS, Dawber TR. The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study. Am J Epidemiol 1977; 106: 33-41.
59. Kahn HA, Milton RC. Alternative definitions of open-angle glaucoma. Effect on prevalence and associations in the Framingham eye study. Arch Ophthalmol 1980; 98: 2172-2177.
60. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714-720; discussion 829-730.
61. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol 2008; 53 Suppl1: S3-S10.
62. Gordon MO, Beiser JA, Kass MA. Is a history of diabetes mellitus protective against developing primary open-angle glaucoma? Arch Ophthalmol 2008; 126: 280-281.
63. Wolter JR. Diabetic retinopathy. Am J Ophthalmol 1961; 51: 1123-1141.
64. Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1995; 1: 527-534.
65. Ino-Ue M, Zhang L, Naka H, Kuriyama H, Yamamoto M. Polyol metabolism of retrograde axonal transport in diabetic rat large optic nerve fiber. Invest Ophthalmol Vis Sci 2000; 41: 4055-4058.
66. Nakamura M, Kanamori A, Negi A. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. Ophthalmologica 2005; 219: 1-10.
67. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003; 52: 506-511.
68. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102: 783-791.
69. Kanamori A, Nakamura M, Mukuno H, Maeda H, Negi A. Diabetes has an additive effect on neural apoptosis in rat retina with chronically elevated intraocular pressure. Curr Eye Res 2004; 28: 47-54.
70. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, Feldman EL. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 1999; 6: 347-363.
71. Oshitari T, Roy S. Diabetes: a potential enhancer of retinal injury in rat retinas. Neurosci Lett 2005; 390: 25-30.
72. Sima AA, Zhang WX, Cherian PV, Chakrabarti S. Impaired visual evoked potential and primary axonopathy of the optic nerve in the diabetic BB/W-rat. Diabetologia 1992; 35: 602-607.
73. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 2000; 17: 463-471.
74. Bui BV, Loeliger M, Thomas M, Vingrys AJ, Rees SM, Nguyen CT, He Z et al. Investigating structural and biochemical correlates of ganglion cell dysfunction in streptozotocin-induced diabetic rats. Exp Eye Res 2009; 88: 1076-1083.
75. Sugimoto M, Sasoh M, Ido M, Wakitani Y, Takahashi C, Uji Y. Detection of early diabetic change with optical coherence tomography in type 2 diabetes mellitus patients without retinopathy. Ophthalmologica 2005; 219: 379-385.
76. van Dijk HW, Kok PH, Garvin M, Sonka M, Devries JH, Michels RP, van Velthoven ME et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 3404-3409.
77. van Dijk HW, Verbraak FD, Kok PH, Garvin MK, Sonka M, Lee K, Devries JH et al. Decreased retinal ganglion cell layer thickness in type 1 diabetic patients. Invest Ophthalmol Vis Sci 2010; 51: 3660-3665.
78. Weinreb RN, Shakiba S, Sample PA, Shahrokni S, van Horn S, Garden VS, Asawaphureekorn S et al. Association between quantitative nerve fiber layer measurement and visual field loss in glaucoma. Am J Ophthalmol 1995; 120: 732-738.
79. Quigley HA, Hohman RM, Addicks EM, Massof RW, Green WR. Morphologic changes in the lamina cribrosa correlated with neural loss in open-angle glaucoma. Am J Ophthalmol 1983; 95: 673-691.
80. Phipps JA, Fletcher EL, Vingrys AJ. Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest Ophthalmol Vis Sci 2004; 45: 4592-4600.
81. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998; 76: 21-31.
82. King GL, Shiba T, Oliver J, Inoguchi T, Bursell SE. Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 1994; 45: 179-188.
83. Yee P, Weymouth AE, Fletcher EL, Vingrys AJ. A role for omega-3 polyunsaturated fatty acid supplements in diabetic neuropathy. Invest Ophthalmol Vis Sci 2010; 51: 1755-1764.
84. Bui BV, Armitage JA, Vingrys AJ. Extraction and modelling of oscillatory potentials. Doc Ophthalmol 2002; 104: 17-36.
85. Forte JD, Bui BV, Vingrys AJ. Wavelet analysis reveals dynamics of rat oscillatory potentials. J Neurosci Methods 2008; 169: 191-200.
86. Coupland SG. A comparison of oscillatory potential and pattern electroretinogram measures in diabetic retinopathy. Doc Ophthalmol 1987; 66: 207-218.
87. Bresnick GH, Palta M. Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol 1987; 105: 929-933.
88. Holopigian K, Seiple W, Lorenzo M, Carr R. A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1992; 33: 2773-2780.
89. Roecker EB, Pulos E, Bresnick GH, Severns M. Characterization of the electroretinographic scotopic B-wave amplitude in diabetic and normal subjects. Invest Ophthalmol Vis Sci 1992; 33: 1575-1583.
90. Uccioli L, Parisi V, Monticone G, Parisi L, Durola L, Pernini C, Neuschuler R et al. Electrophysiological assessment of visual function in newly-diagnosed IDDM patients. Diabetologia 1995; 38: 804-808.
91. Sakai H, Tani Y, Shirasawa E, Shirao Y, Kawasaki K. Development of electroretinographic alterations in streptozotocin-induced diabetes in rats. Ophthalmic Res 1995; 27: 57-63.
92. Ramsey DJ, Ripps H, Qian H. An electrophysiological study of retinal function in the diabetic female rat. Invest Ophthalmol Vis Sci 2006; 47: 5116-5124.
93. Kizawa J, Machida S, Kobayashi T, Gotoh Y, Kurosaka D. Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn J Ophthalmol 2006; 50: 367-373.
94. Shinoda K, Rejdak R, Schuettauf F, Blatsios G, Volker M, Tanimoto N, Olcay T et al. Early electroretinographic features of streptozotocin-induced diabetic retinopathy. Clin Experiment Ophthalmol 2007; 35: 847-854.
95. Dong CJ, Hare WA. GABAc feedback pathway modulates the amplitude and kinetics of ERG b-wave in a mammalian retina in vivo. Vision Res 2002; 42: 1081-1087.
96. Wachtmeister L, Dowling JE. The oscillatory potentials of the mudpuppy retina. Invest Ophthalmol Vis Sci 1978; 17: 1176-1188.
97. Matthews GP, Crane WG, Sandberg MA. Effects of 2-amino-4-phosphonobutyric acid (APB) and glycine on the oscillatory potentials of the rat electroretinogram. Exp Eye Res 1989; 49: 777-787.
98. Wachtmeister L. Further studies of the chemical sensitivity of the oscillatory potentials of the electroretinogram (ERG) I. GABA- and glycine antagonists. Acta Ophthalmol (Copenh) 1980; 58: 712-725.
99. Gastinger MJ, Singh RS, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 2006; 47: 3143-3150.
100. Li X, Sun X, Hu Y, Huang J, Zhang H. Electroretinographic oscillatory potentials in diabetic retinopathy. An analysis in the domains of time and frequency. Doc Ophthalmol 1992; 81: 173-179.
101. Van der Torren K, Groeneweg G, van Lith G. Measuring oscillatory potentials: Fourier analysis. Doc Ophthalmol 1988; 69: 153-159.
102. Layton CJ, Safa R, Osborne NN. Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1335-1345.
103. Weisinger H, Vingrys A, Sinclair A. Electrodiagnostic methods in vision, Part 3 Clinical electrophysiology. Clin Exp Optom 1996; 79: 131-143.
104. Parisi V, Uccioli L. Visual electrophysiological responses in persons with type 1 diabetes. Diabetes Metab Res Rev 2001; 17: 12-18.
105. Viswanathan S, Frishman LJ, Robson JG, Harwerth RS, Smith EL 3rd. The photopic negative response of the macaque electroretinogram: reduction by experimental glaucoma. Invest Ophthalmol Vis Sci 1999; 40: 1124-1136.
106. Viswanathan S, Frishman LJ, Robson JG. The uniform field and pattern ERG in macaques with experimental glaucoma: removal of spiking activity. Invest Ophthalmol Vis Sci 2000; 41: 2797-2810.
107. Rangaswamy NV, Frishman LJ, Dorotheo EU, Schiffman JS, Bahrani HM, Tang RA. Photopic ERGs in patients with optic neuropathies: comparison with primate ERGs after pharmacologic blockade of inner retina. Invest Ophthalmol Vis Sci 2004; 45: 3827-3837.
108. Rangaswamy NV, Zhou W, Harwerth RS, Frishman LJ. Effect of experimental glaucoma in primates on oscillatory potentials of the slow-sequence mfERG. Invest Ophthalmol Vis Sci 2006; 47: 753-767.
109. Sieving PA, Frishman LJ, Steinberg RH. Scotopic threshold response of proximal retina in cat. J Neurophysiol 1986; 56: 1049-1061.
110. Sieving PA, Nino C. Scotopic threshold response (STR) of the human electroretinogram. Invest Ophthalmol Vis Sci 1988; 29: 1608-1614.
111. Frishman LJ, Shen FF, Du L, Robson JG, Harwerth RS, Smith EL 3rd, Carter-Dawson L et al. The scotopic electroretinogram of macaque after retinal ganglion cell loss from experimental glaucoma. Invest Ophthalmol Vis Sci 1996; 37: 125-141.
112. Frishman LJ, Steinberg RH. Intraretinal analysis of the threshold dark-adapted ERG of cat retina. J Neurophysiol 1989; 61: 1221-1232.
113. Bui BV, Fortune B. Ganglion cell contributions to the rat full-field electroretinogram. J Physiol 2004; 555: 153-173.
114. Saszik SM, Robson JG, Frishman LJ. The scotopic threshold response of the dark-adapted electroretinogram of the mouse. J Physiol 2002; 543: 899-916.
115. He Z, Bui BV, Vingrys AJ. The rate of functional recovery from acute IOP elevation. Invest Ophthalmol Vis Sci 2006; 47: 4872-4880.
116. Fortune B, Bui BV, Morrison JC, Johnson EC, Dong J, Cepurna WO, Jia L et al. Selective ganglion cell functional loss in rats with experimental glaucoma. Invest Ophthalmol Vis Sci 2004; 45: 1854-1862.
117. Kohzaki K, Vingrys AJ, Bui BV. Early inner retinal dysfunction in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2008; 49: 3595-3604.
118. Vesti E, Trick GL. Diabetes can alter the interpretation of visual dysfunction in ocular hypertension. Ophthalmology 1996; 103: 1419-1425.
119. Quigley HA, Enger C, Katz J, Sommer A, Scott R, Gilbert D. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol 1994; 112: 644-649.
120. Casson RJ, Chidlow G, Wood JP, Osborne NN. The effect of hyperglycemia on experimental retinal ischemia. Arch Ophthalmol 2004; 122: 361-366.
121. Holman MC, Chidlow G, Wood JP, Casson RJ. The effect of hyperglycemia on hypoperfusion-induced injury. Invest Ophthalmol Vis Sci 2010; 51: 2197-2207.
122. Kim C, Kim TW. Comparison of risk factors for bilateral and unilateral eye involvement in normal-tension glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 1215-1220.
123. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, Wong H et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000; 43: 312-320.
124. Huang YS, Horrobin DF, Manku MS, Mitchell J, Ryan MA. Tissue phospholipid fatty acid composition in the diabetic rat. Lipids 1984; 19: 367-370.
125. Chattopadhyay J, Thompson EW, Schmid HH. Nonesterified fatty acids in normal and diabetic rat sciatic nerve. Lipids 1992; 27: 513-517.
126. Ruiz-Gutierrez V, Stiefel P, Villar J, Garcia-Donas MA, Acosta D, Carneado J. Cell membrane fatty acid composition in type 1 (insulin-dependent) diabetic patients: relationship with sodium transport abnormalities and metabolic control. Diabetologia 1993; 36: 850-856.
127. Ghebremeskel K, Thomas B, Lowy C, Min Y, Crawford MA. Type 1 diabetes compromises plasma arachidonic and docosahexaenoic acids in newborn babies. Lipids 2004; 39: 335-342.
128. de Gomez Dumm IN, Montenegro S, Tarrés MC, Martinez SM, Igal RA. Early lipid alterations in spontaneously diabetic rats. Acta Physiol Pharmacol Ther Latinoam 1998; 48: 228-234.
129. Nguyen CT, Vingrys AJ, Bui BV. Dietary omega-3 fatty acids and ganglion cell function. Invest Ophthalmol Vis Sci 2008; 49: 3586-3594.
130. Weisinger HS, Vingrys AJ, Bui BV, Sinclair AJ. Effects of dietary n-3 fatty acid deficiency and repletion in the guinea pig retina. Invest Ophthalmol Vis Sci 1999; 40: 327-338.
131. Bazan NG. Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor Lecture. Invest Ophthalmol Vis Sci 2007; 48: 4866-4881; biography 4864-4865.
132. Bazan NG. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. Curr Opin Clin Nutr Metab Care 2007; 10: 136-141.
133. Krauss RM, Siri PW. Dyslipidemia in type 2 diabetes. Med Clin North Am 2004; 88: 897-909.
134. Glatz JF, Luiken JJ, Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev 2010; 90: 367-417.
135. Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother 2002; 56: 215-222.
136. Calder PC. Effects of fatty acids and dietary lipids on cells of the immune system. Proc Nutr Soc 1996; 55: 127-150.
137. Tezel G, Wax MB. The immune system and glaucoma. Curr Opin Ophthalmol 2004; 15: 80-84.
138. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res 2005; 24: 87-138.
139. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001; 20: 705-732.
140. Tang J, Zhu XW, Lust WD, Kern TS. Retina accumulates more glucose than does the embryologically similar cerebral cortex in diabetic rats. Diabetologia 2000; 43: 1417-1423.
141. Kim DI, Lim SK, Park MJ, Han HJ, Kim GY, Park SH. The involvement of phosphatidylinositol 3-kinase/Akt signaling in high glucose-induced downregulation of GLUT-1 expression in ARPE cells. Life Sci 2007; 80: 626-632.
142. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J Glaucoma 2009; 18: 93-100.
143. Lin J, Feng Y, Hagen F, Hammes H-P. Cellular crosstalk under hyperglycemic stress: the diabetic retina as a paradigm. Internat Congress Series 2004; 1262: 156-159.
144. Su EN, Alder VA, Yu DY, Yu PK, Cringle SJ, Yogesan K. Continued progression of retinopathy despite spontaneous recovery to normoglycemia in a long-term study of streptozotocin-induced diabetes in rats. Graefes Arch Clin Exp Ophthalmol 2000; 238: 163-173.
145. Speiser P, Gittelsohn AM, Patz A. Studies on diabetic retinopathy. 3. Influence of diabetes on intramural pericytes. Arch Ophthalmol 1968; 80: 332-337.
146. Hammes HP. Pericytes and the pathogenesis of diabetic retinopathy. Horm Metab Res 2005; 37 Suppl 1: 39-43.
147. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care 1998; 21: 143-156.
148. Harhaj NS, Felinski EA, Wolpert EB, Sundstrom JM, Gardner TW, Antonetti DA. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006; 47: 5106-5115.
149. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res 2004; 28: 251-256.
150. Sone H, Kawakami Y, Okuda Y, Sekine Y, Honmura S, Matsuo K, Segawa T et al. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia 1997; 40: 726-730.
151. Ambati J, Chalam KV, Chawla DK, D'Angio CT, Guillet EG, Rose SJ, Vanderlinde RE et al. Elevated gamma-aminobutyric acid, glutamate, and vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 1997; 115: 1161-1166.
152. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med 2005; 353: 839-841.
153. Sone H, Okuda Y, Kawakami Y, Hanatani M, Suzuki H, Kozawa T, Honmura S et al. Vascular endothelial growth factor level in aqueous humor of diabetic patients with rubeotic glaucoma is markedly elevated. Diabetes Care 1996; 19: 1306-1307.
154. Higashi S, Clermont AC, Dhir V, Bursell SE. Reversibility of retinal flow abnormalities is disease-duration dependent in diabetic rats. Diabetes 1998; 47: 653-659.
155. Clermont AC, Bursell SE. Retinal blood flow in diabetes. Microcirculation 2007; 14: 49-61.
156. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996; 37: 886-897.
157. Wangsa-Wirawan ND, Linsenmeier RA. Retinal oxygen: fundamental and clinical aspects. Arch Ophthalmol 2003; 121: 547-557.
158. Yu PK, Yu DY, Alder VA, Su EN, Cringle SJ. Intracellular structures of retinal vascular endothelium in normal and early diabetic rats. Aust N Z J Ophthalmol 1998; 26 Suppl 1: S53-55.
159. Cringle SJ, Yu DY, Alder VA, Su EN. Retinal blood flow by hydrogen clearance polarography in the streptozotocin-induced diabetic rat. Invest Ophthalmol Vis Sci 1993; 34: 1716-1721.
160. Pemp B, Schmetterer L. Ocular blood flow in diabetes and age-related macular degeneration. Can J Ophthalmol 2008; 43: 295-301.
161. Bek T, Hajari J, Jeppesen P. Interaction between flicker-induced vasodilatation and pressure autoregulation in early retinopathy of type 2 diabetes. Graefes Arch Clin Exp Ophthalmol 2008; 246: 763-769.
162. Toda N, Nakanishi-Toda M. Nitric oxide: ocular blood flow, glaucoma and diabetic retinopathy. Prog Retin Eye Res 2007; 26: 205-238.
163. Flammer J, Mozaffarieh M. Autoregulation, a balancing act between supply and demand. Can J Ophthalmol 2008; 43: 317-321.
164. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004; 10: 3331-3348.
165. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996; 271: 2746-2753.
166. Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res 2006; 83: 473-483.
167. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
168. Danylkova NO, Pomeranz HD, Alcala SR, McLoon LK. Histological and morphometric evaluation of transient retinal and optic nerve ischemia in rat. Brain Res 2006; 1096: 20-29.
169. Tezel G, Wax MB. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol 2004; 122: 1348-1356.
170. Arden GB, Sidman RL, Arap W, Schlingemann RO. Spare the rod and spoil the eye. Br J Ophthalmol 2005; 89: 764-769.
171. Arden GB. The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment. Br J Ophthalmol 2001; 85: 366-370.
172. de Gooyer TE, Stevenson KA, Humphries P, Simpson DA, Gardiner TA, Stitt AW. Retinopathy is reduced during experimental diabetes in a mouse model of outer retinal degeneration. Invest Ophthalmol Vis Sci 2006; 47: 5561-5568.
173. Yu DY, Cringle SJ, Su EN, Yu PK, Jerums G, Cooper ME. Pathogenesis and intervention strategies in diabetic retinopathy. Clin Experiment Ophthalmol 2001; 29: 164-166.
174. Van den Enden MK, Nyengaard JR, Ostrow E, Burgan JH, Williamson JR. Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Implications for diabetic retinopathy. Invest Ophthalmol Vis Sci 1995; 36: 1675-1685.
175. Soulis T, Thallas V, Youssef S, Gilbert RE, McWilliam BG, Murray-McIntosh RP, Cooper ME. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 1997; 40: 619-628.
176. Fox TE, Han X, Kelly S, Merrill AH 2nd, Martin RE, Anderson RE, Gardner TW et al. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes 2006; 55: 3573-3580.
177. Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol Rev 1998; 50: 21-33.
178. Tomlinson DR. Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 1999; 42: 1271-1281.
179. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol 1997; 115: 497-503.
180. Engerman RL, Kern TS. Experimental galactosemia produces diabetic-like retinopathy. Diabetes 1984; 33: 97-100.
181. Schmetterer L, Wolzt M. Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia 1999; 42: 387-405.
182. Ellis EA, Grant MB, Murray FT, Wachowski MB, Guberski DL, Kubilis PS, Lutty GA. Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 1998; 24: 111-120.
183. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-813.
184. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S et al. Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 2006; 55: 1946-1953.
185. Winkler BS, Arnold MJ, Brassell MA, Sliter DR. Glucose dependence of glycolysis, hexose monophosphate shunt activity, energy status, and the polyol pathway in retinas isolated from normal (nondiabetic) rats. Invest Ophthalmol Vis Sci 1997; 38: 62-71.
186. Diederen RM, Starnes CA, Berkowitz BA, Winkler BS. Re-examining the hyperglycemic pseudohypoxia hypothesis of diabetic oculopathy. Invest Ophthalmol Vis Sci 2006; 47: 2726-2731.
187. Tilton RG. Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF. Microsc Res Tech 2002; 57: 390-407.
188. Alexander JP, Acott TS. Involvement of protein kinase C in TNFalpha regulation of trabecular matrix metalloproteinases and TIMPs. Invest Ophthalmol Vis Sci 2001; 42: 2831-2838.
189. Khurana RN, Deng PF, Epstein DL, Vasantha Rao P. The role of protein kinase C in modulation of aqueous humor outflow facility. Exp Eye Res 2003; 76: 39-47.
190. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res 2002; 21: 1-14.
191. Kuehn MH, Fingert JH, Kwon YH. Retinal ganglion cell death in glaucoma: mechanisms and neuroprotective strategies. Ophthalmol Clin North Am 2005; 18: 383-395, vi.
192. Else PL, Wu BJ. What role for membranes in determining the higher sodium pump molecular activity of mammals compared to ectotherms? J Comp Physiol B 1999; 169: 296-302.
193. Gerbi A, Zerouga M, Debray M, Durand G, Chanez C, Bourre JM. Effect of dietary alpha-linolenic acid on functional characteristic of Na+/K(+)-ATPase isoenzymes in whole brain membranes of weaned rats. Biochim Biophys Acta 1993; 1165: 291-298.
194. Baylor DA, Matthews G, Nunn BJ. Location and function of voltage-sensitive conductances in retinal rods of the salamander, Ambystoma tigrinum. J Physiol 1984; 354: 203-223.
195. Baylor DA, Lamb TD, Yau KW. The membrane current of single rod outer segments. J Physiol 1979; 288: 589-611.
196. Yau KW, Lamb TD, Matthews G, Baylor DA. Current fluctuations across single rod outer segments. Vision Res 1979; 19: 387-390.
197. Phipps JA, Yee P, Fletcher EL, Vingrys AJ. Rod photoreceptor dysfunction in diabetes: activation, deactivation, and dark adaptation. Invest Ophthalmol Vis Sci 2006; 47: 3187-3194.
198. MacGregor LC, Matschinsky FM. Altered retinal metabolism in diabetes. II. Measurement of sodium-potassium ATPase and total sodium and potassium in individual retinal layers. J Biol Chem 1986; 261: 4052-4058.
199. Hatou S, Yamada M, Mochizuki H, Nishida T. Role of protein kinase C in regulation of Na+- and K +-dependent ATPase activity and pump function in corneal endothelial cells. Jpn J Ophthalmol 2009; 53: 235-242.
200. Ames A, 3rd, Li YY, Heher EC, Kimble CR. Energy metabolism of rabbit retina as related to function: high cost of Na+ transport. J Neurosci 1992; 12: 840-853.
201. Roufail E, Soulis T, Boel E, Cooper ME, Rees S. Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Diabetologia 1998; 41: 1419-1425.
202. Li Q, Zemel E, Miller B, Perlman I. NADPH diaphorase activity in the rat retina during the early stages of experimental diabetes. Graefes Arch Clin Exp Ophthalmol 2003; 241: 747-756.
203. Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N, Savli H. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye (Lond) 2002; 16: 163-170.
204. Ozden S, Tatlipinar S, Bicer N, Yaylali V, Yildirim C, Ozbay D, Guner G. Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different stages of retinopathy. Can J Ophthalmol 2003; 38: 393-396.
205. Abu El-Asrar AM, Desmet S, Meersschaert A, Dralands L, Missotten L, Geboes K. Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. Am J Ophthalmol 2001; 132: 551-556.
206. Kowluru RA. Diabetes-induced elevations in retinal oxidative stress, protein kinase C and nitric oxide are interrelated. Acta Diabetol 2001; 38: 179-185.
207. Goto R, Doi M, Ma N, Semba R, Uji Y. Contribution of nitric oxide-producing cells in normal and diabetic rat retina. Jpn J Ophthalmol 2005; 49: 363-370.
208. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des 2007; 13: 2699-2712.
209. Kawasaki A, Otori Y, Barnstable CJ. Müller cell protection of rat retinal ganglion cells from glutamate and nitric oxide neurotoxicity. Invest Ophthalmol Vis Sci 2000; 41: 3444-3450.
210. Kalloniatis M, Tomisich G. Amino acid neurochemistry of the vertebrate retina. Prog Retin Eye Res 1999; 18: 811-866.
211. Nicolela MT, Hnik P, Drance SM. Scanning laser Doppler flowmeter study of retinal and optic disk blood flow in glaucomatous patients. Am J Ophthalmol 1996; 122: 775-783.
212. Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2010; 2: CD006539.
213. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull 2004; 62: 455-459.
214. Vidal L, Diaz F, Villena A, Moreno M, Campos JG, de Vargas IP. Nitric oxide synthase in retina and optic nerve head of rat with increased intraocular pressure and effect of timolol. Brain Res Bull 2006; 70: 406-413.
215. Chiou GC. Review: effects of nitric oxide on eye diseases and their treatment. J Ocul Pharmacol Ther 2001; 17: 189-198.
216. Tomlinson DR, Fernyhough P, Diemel LT. Neurotrophins and peripheral neuropathy. Philos Trans R Soc Lond B Biol Sci 1996; 351: 455-462.
217. Zhang L, Ino-ue M, Dong K, Yamamoto M. Retrograde axonal transport impairment of large- and medium-sized retinal ganglion cells in diabetic rat. Curr Eye Res 2000; 20: 131-136.
218. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002; 50: 393-413.
219. Rodriguez-Pena A, Botana M, Gonzalez M, Requejo F. Expression of neurotrophins and their receptors in sciatic nerve of experimentally diabetic rats. Neurosci Lett 1995; 200: 37-40.
220. Fernyhough P, Diemel LT, Tomlinson DR. Target tissue production and axonal transport of neurotrophin-3 are reduced in streptozotocin-diabetic rats. Diabetologia 1998; 41: 300-306.
221. Seigel GM, Lupien SB, Campbell LM, Ishii DN. Systemic IGF-I treatment inhibits cell death in diabetic rat retina. J Diabetes Complications 2006; 20: 196-204.
222. Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, Abe H, Takei N. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 2004; 53: 2412-2419.
223. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, Fischer CP et al. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007; 50: 431-438.
224. Minckler DS, Bunt AH, Johanson GW. Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey. Invest Ophthalmol Vis Sci 1977; 16: 426-441.
225. Quigley HA, Anderson DR. Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. Invest Ophthalmol Vis Sci 1977; 16: 640-644.
226. Balaratnasingam C, Morgan WH, Bass L, Matich G, Cringle SJ, Yu DY. Axonal transport and cytoskeletal changes in the laminar regions after elevated intraocular pressure. Invest Ophthalmol Vis Sci 2007; 48: 3632-3644.
227. Abu El-Asrar AM, Van den Steen PE, Al-Amro SA, Missotten L, Opdenakker G, Geboes K. Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int Ophthalmol 2007; 27: 11-22.
228. Kuiper EJ, Witmer AN, Klaassen I, Oliver N, Goldschmeding R, Schlingemann RO. Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. Br J Ophthalmol 2004; 88: 1082-1087.
229. Tikellis C, Cooper ME, Twigg SM, Burns WC, Tolcos M. Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. Endocrinology 2004; 145: 860-866.
230. Daniels JT, Schultz GS, Blalock TD, Garrett Q, Grotendorst GR, Dean NM, Khaw PT. Mediation of transforming growth factor-beta(1)-stimulated matrix contraction by fibroblasts: a role for connective tissue growth factor in contractile scarring. Am J Pathol 2003; 163: 2043-2052.
231. Shimo T, Nakanishi T, Nishida T, Asano M, Kanyama M, Kuboki T, Tamatani T et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 1999; 126: 137-145.
232. Hishikawa K, Nakaki T, Fujii T. Connective tissue growth factor induces apoptosis via caspase 3 in cultured human aortic smooth muscle cells. Eur J Pharmacol 2000; 392: 19-22.
233. Ho SL, Dogar GF, Wang J, Crean J, Wu QD, Oliver N, Weitz S et al. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br J Ophthalmol 2005; 89: 169-173.
234. Liton PB, Liu X, Challa P, Epstein DL, Gonzalez P. Induction of TGF-beta1 in the trabecular meshwork under cyclic mechanical stress. J Cell Physiol 2005; 205: 364-371.
235. Bellezza AJ, Hart RT, Burgoyne CF. The optic nerve head as a biomechanical structure: initial finite element modeling. Invest Ophthalmol Vis Sci 2000; 41: 2991-3000.
236. Sigal IA, Flanagan JG, Tertinegg I, Ethier CR. Modeling individual-specific human optic nerve head biomechanics. Part I: IOP-induced deformations and influence of geometry. Biomech Model Mechanobiol 2009; 8: 85-98.
237. Downs JC, Roberts MD, Burgoyne CF. Mechanical environment of the optic nerve head in glaucoma. Optom Vis Sci 2008; 85: 425-435.
238. Sigal IA, Ethier CR. Biomechanics of the optic nerve head. Exp Eye Res 2009; 88: 799-807.
239. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D, Strother JM. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998; 47: 815-820.
240. Newman E, Reichenbach A. The Müller cell: a functional element of the retina. Trends Neurosci 1996; 19: 307-312.
241. Pena JD, Varela HJ, Ricard CS, Hernandez MR. Enhanced tenascin expression associated with reactive astrocytes in human optic nerve heads with primary open angle glaucoma. Exp Eye Res 1999; 68: 29-40.
242. Kobayashi S, Vidal I, Pena JD, Hernandez MR. Expression of neural cell adhesion molecule (NCAM) characterizes a subpopulation of type 1 astrocytes in human optic nerve head. Glia 1997; 20: 262-273.
243. Pena JD, Agapova O, Gabelt BT, Levin LA, Lucarelli MJ, Kaufman PL, Hernandez MR. Increased elastin expression in astrocytes of the lamina cribrosa in response to elevated intraocular pressure. Invest Ophthalmol Vis Sci 2001; 42: 2303-2314.
244. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, Schwartz M. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma. Proc Natl Acad Sci USA 2001; 98: 3398-3403.
245. Wax MB, Tezel G, Yang J, Peng G, Patil RV, Agarwal N, Sappington RM et al. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci 2008; 28: 12085-12096.
246. Stasi K, Nagel D, Yang X, Wang RF, Ren L, Podos SM, Mittag T et al. Complement component 1Q (C1Q) upregulation in retina of murine, primate, and human glaucomatous eyes. Invest Ophthalmol Vis Sci 2006; 47: 1024-1029.
247. Elkington AR, Inman CB, Steart PV, Weller RO. The structure of the lamina cribrosa of the human eye: an immunocytochemical and electron microscopical study. Eye (Lond) 1990; 4: 42-57.
248. Sun D, Lye-Barthel M, Masland RH, Jakobs TC. The morphology and spatial arrangement of astrocytes in the optic nerve head of the mouse. J Comp Neurol 2009; 516: 1-19.
249. Varela HJ, Hernandez MR. Astrocyte responses in human optic nerve head with primary open-angle glaucoma. J Glaucoma 1997; 6: 303-313.
250. Balaratnasingam C, Morgan WH, Bass L, Ye L, McKnight C, Cringle SJ, Yu DY. Elevated pressure induced astrocyte damage in the optic nerve. Brain Res 2008; 1244: 142-154.
251. Balaratnasingam C, Morgan WH, Bass L, Cringle SJ, Yu DY. Time-dependent effects of elevated intraocular pressure on optic nerve head axonal transport and cytoskeleton proteins. Invest Ophthalmol Vis Sci 2008; 49: 986-999.
252. Morgan JE. Optic nerve head structure in glaucoma: astrocytes as mediators of axonal damage. Eye (Lond) 2000; 14: 437-444.
253. Leist M, Nicotera P. Calcium and neuronal death. Rev Physiol Biochem Pharmacol 1998; 132: 79-125.
254. Hartwick AT, Lalonde MR, Barnes S, Baldridge WH. Adenosine A1-receptor modulation of glutamate-induced calcium influx in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2004; 45: 3740-3748.
255. Ward MM, Jobling AI, Kalloniatis M, Fletcher EL. Glutamate uptake in retinal glial cells during diabetes. Diabetologia 2005; 48: 351-360.
256. Kowluru RA, Engerman RL, Case GL, Kern TS. Retinal glutamate in diabetes and effect of antioxidants. Neurochem Int 2001; 38: 385-390.
257. Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells. Invest Ophthalmol Vis Sci 2002; 43: 3109-3116.
258. Roberts MD, Grau V, Grimm J, Reynaud J, Bellezza AJ, Burgoyne CF, Downs JC. Remodeling of the connective tissue microarchitecture of the lamina cribrosa in early experimental glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 681-690.
259. Yang H, Downs JC, Burgoyne CF. Physiologic inter-eye differences in monkey optic nerve head architecture and their relation to changes in early experimental glaucoma. Invest Ophthalmol Vis Sci 2009; 50: 224-234.
260. Johnson EC, Morrison JC, Farrell S, Deppmeier L, Moore CG, McGinty MR. The effect of chronically elevated intraocular pressure on the rat optic nerve head extracellular matrix. Exp Eye Res 1996; 62: 663-674.
261. Morgan JE, Jeffery G, Foss AJ. Axon deviation in the human lamina cribrosa. Br J Ophthalmol 1998; 82: 680-683.
262. Quigley HA, Guy J, Anderson DR. Blockade of rapid axonal transport. Effect of intraocular pressure elevation in primate optic nerve. Arch Ophthalmol 1979; 97: 525-531.
263. Francis-Sedlak ME, Uriel S, Larson JC, Greisler HP, Venerus DC, Brey EM. Characterization of type I collagen gels modified by glycation. Biomaterials 2009; 30: 1851-1856.
264. Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, Nickerson RJ et al. The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980; 24: 335-610.
265. Le A, Mukesh BN, McCarty CA, Taylor HR. Risk factors associated with the incidence of open-angle glaucoma: the visual impairment project. Invest Ophthalmol Vis Sci 2003; 44: 3783-3789.
266. Hennis A, Wu SY, Nemesure B, Leske MC. Hypertension, diabetes and longitudinal changes in intraocular pressure. Ophthalmology 2003; 110: 908-914.
267. Pasquale LR, Kang JH, Manson JE, Willett WC, Rosner BA, Hankinson SE. Prospective study of type 2 diabetes mellitus and risk of primary open-angle glaucoma in women. Ophthalmology 2006; 113: 1081-1086.
268. Miglior S, Pfeiffer N, Torri V, Zeyen T, Cunha-Vaz J, Adamsons I. Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. Ophthalmology 2007; 114: 3-9.
269. Chopra V, Varma R, Francis BA, Wu J, Torres M, Azen SP. Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino Eye Study. Ophthalmology 2008; 115: 227-232.
270. Ciulla TA, Harris A, Latkany P, Piper HC, Arend O, Garzozi H, Martin B. Ocular perfusion abnormalities in diabetes. Acta Ophthalmol Scand 2002; 80: 468-477.
271. Pemp B, Georgopoulos M, Vass C, Fuchsjager-Mayrl G, Luksch A, Rainer G, Schmetterer L. Diurnal fluctuation of ocular blood flow parameters in patients with primary open-angle glaucoma and healthy subjects. Br J Ophthalmol 2009; 93: 486-491.
272. Su EN, Yu DY, Alder VA, Yu PK, Cringle SJ. Altered vasoactivity in the early diabetic eye: measured in the isolated perfused rat eye. Exp Eye Res 1995; 61: 699-711.
273. Nathanson JA, McKee M. Alterations of ocular nitric oxide synthase in human glaucoma. Invest Ophthalmol Vis Sci 1995; 36: 1774-1784.
274. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res 1995; 61: 33-44.
275. Quigley HA. Ganglion cell death in glaucoma: pathology recapitulates ontogeny. Aust NZ J Ophthalmol 1995; 23: 85-91.
276. Gao H, Qiao X, Cantor LB, WuDunn D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002; 120: 797-803.
277. Chintala SK, Zhang X, Austin JS, Fini ME. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J Biol Chem 2002; 277: 47461-47468.